• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: President & CEO Lebovits Chaim bought $18,865 worth of shares (40,000 units at $0.47), increasing direct ownership by 4% to 1,099,865 units (SEC Form 4)

    7/31/24 4:07:56 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lebovits Chaim

    (Last) (First) (Middle)
    C/O BRAINSTORM CELL THERAPEUTICS INC.
    1325 AVENUE OF THE AMERICAS 28TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    05/10/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    05/14/2024
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/10/2024 P(1) 20,000 A $0.465 1,079,865 D
    Common Stock 05/11/2024 P(1) 10,000 A $0.4665 1,089,865 D
    Common Stock 05/13/2024 P(1) 10,000 A $0.49 1,099,865 D
    Common Stock 2,000,847 I See footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'.
    2. Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 67,053 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.
    /s/ Chaim Lebovits 07/31/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Leadership Updates

    Live Leadership Updates

    See more
    • BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

      Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.     Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil

      6/20/24 6:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

      Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin

      7/12/23 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

      NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further

      6/20/23 9:06:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

      NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m. Eastern Time. BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Haro Hart

      5/15/25 7:30:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainstorm Cell upgraded by Maxim Group

      Maxim Group upgraded Brainstorm Cell from Hold to Buy

      2/5/21 8:55:41 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

      2/4/21 1:51:23 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BCLI
    SEC Filings

    See more

    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • President & CEO Lebovits Chaim bought $11,308 worth of shares (23,836 units at $0.47), decreasing direct ownership by 93% to 80,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      10/2/24 8:00:14 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $7,774 worth of shares (15,000 units at $0.52), increasing direct ownership by 1% to 1,164,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:09:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $30,475 worth of shares (50,000 units at $0.61), increasing direct ownership by 5% to 1,149,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:08:32 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Dagher Ibrahim B. was granted 50,000 shares, increasing direct ownership by 297% to 66,849 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:11:08 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Dagher Ibrahim B. claimed ownership of 505,742 shares (SEC Form 3)

      3/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:10:10 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Lebovits Chaim was granted 120,000 shares, increasing direct ownership by 148% to 200,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/3/25 5:36:42 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/19/25 4:10:20 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc.

      DEFA14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/16/25 7:05:15 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Brainstorm Cell Therapeutics Inc.

      DEF 14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/16/25 7:00:31 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/14/24 3:24:53 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/13/24 7:55:51 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

      SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      2/12/24 10:06:24 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

      NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

      5/27/25 7:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care